CSIMarket
 
Accelerate Diagnostics Inc   (AXDX)
Other Ticker:  
 
 
Price: $0.9700 $-0.02 -1.533%
Day's High: $1.08 Week Perf: 1.04 %
Day's Low: $ 0.95 30 Day Perf: -27.07 %
Volume (M): 22 52 Wk High: $ 8.72
Volume (M$): $ 21 52 Wk Avg: $3.39
Open: $1.03 52 Wk Low: $0.45



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 15
 Employees -
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -63
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 1

Accelerate Diagnostics Inc
Accelerate Diagnostics Inc is a medical technology company that is focused on the development and commercialization of innovative diagnostic solutions. The company's flagship product is the Accelerate Pheno' system, which is designed to provide rapid identification and antibiotic susceptibility testing for infectious diseases. By utilizing advanced molecular and phenotypic technologies, the system aims to help healthcare providers make quicker and more informed treatment decisions. The company is headquartered in Tucson, Arizona and operates globally, serving hospitals and clinical laboratories worldwide.


   Company Address: 3950 South Country Club Road, Tucson, 85714 AZ
   Company Phone Number: 365-3100   Stock Exchange / Ticker: NASDAQ AXDX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Accelerate Diagnostics Inc

Accelerate Diagnostics Inc Suffers Sharp Downturn in Q3 2023 - A Closer Look



Accelerate Diagnostics Inc, a leading Laboratory Analytical Instruments company, has seen its stock experience a notable increase over the past seven days, contributing to a remarkable year-to-date performance. Despite facing a decline in revenue and the challenging impact of the pandemic, the company has managed to turn a profit in the July to September 30, 2023 period. This article will examine the financial results and discuss how they may impact the company in the future.
Positive Turnaround:
During the July to September 30, 2023 period, Accelerate Diagnostics Inc achieved a significant milestone by recording an income per share of $0.06. This marks a substantial improvement compared to the previous year when the company reported a loss of $0.18 per share. Moreover, the earnings per share have turned positive from a significant loss of $-2.97 per share in the previous reporting season. This positive financial turnaround is certainly a promising sign for Accelerate Diagnostics Inc.

Accelerate Diagnostics Inc

Lab Instruments Giant, Accelerate Diagnostics Inc, Faces Revenue Drop and Mounting Losses in Recent Fiscal Period

Accelerate Diagnostics Inc (AXDX) has reported an increase in losses for the fiscal time-frame ending June 30, 2023, primarily due to weak demand. The net loss per share advanced to $-2.97 from $-0.24, indicating a significant decline in profitability. Additionally, the company's revenue witnessed a decline of 27.506%, amounting to $2.80 million compared to $3.86 million in the previous year.
In comparison to the previous quarter, there was a slight decrease in revenue by 0.462%, from $2.81 million. Furthermore, there was a surge in loss per share from $-0.17. These figures highlight the ongoing struggles faced by Accelerate Diagnostics Inc in maintaining a stable financial performance.
For the financial time-frame ending June 30, 2023, Accelerate Diagnostics Inc recorded a net loss of $-32.735 million, surpassing the loss of $-18.523 million reported a year ago. This reflects a continuing trend of declining profitability for the company.

Accelerate Diagnostics Inc

Accelerate Diagnostics Inc. Faces Dire Straits as Revenue Plummeted by Nearly 5% in Recent Fiscal Period

Accelerate Diagnostics Inc. (AXDX) has been performing dismally, as evidenced by its latest financial results for the first quarter of 2023. The company has been making significant losses, and its revenue has been declining, making it a risky investment option. The company's inability to generate profits and increase revenue raises concerns about its long-term viability, making it an unfavorable choice for investors.
For the first quarter of 2023, AXDX reported a loss of $-0.17 per share, compared to $-0.20 per share in the previous year. Despite this slight reduction, the company's loss grew from $-0.12 per share in the previous reporting season. This means that the company's financial performance is not improving, creating doubts about its ability to turn its fortunes around.






 

Accelerate Diagnostics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com